{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:02:08Z","timestamp":1787500928453,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41401-024-01396-4","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T05:03:08Z","timestamp":1730955788000},"page":"515-524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["How improvements in US FDA regulatory process and procedures led to the drug approval for first ever treatment of a common liver disease"],"prefix":"10.1038","volume":"46","author":[{"given":"Brian E.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"1396_CR1","doi-asserted-by":"crossref","unstructured":"Ratziua V, Bellentanib S, Cortez-Pintoc H, Dayd C, Marchesinie G. A position statement on NAFLD\/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372\u201384. https:\/\/www.journal-of-hepatology.eu\/action\/showPdf?pii=S0168-8278%2810%2900414-9","DOI":"10.1016\/j.jhep.2010.04.008"},{"key":"1396_CR2","first-page":"697","volume":"19","author":"ME Rinella","year":"2023","unstructured":"Rinella ME. Examining the nomenclature change from NAFLD and NASH to MASLD and MASH. Gastroenterol Hepatol (NY). 2023;19:697\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10882866\/pdf\/GH_19_11_697.pdf","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"1396_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","volume":"44","author":"M Ekstedt","year":"2006","unstructured":"Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865\u201373. https:\/\/doi.org\/10.1002\/hep.21327","journal-title":"Hepatology"},{"key":"1396_CR4","first-page":"511","volume":"19","author":"GR Lichtenstein","year":"2023","unstructured":"Lichtenstein GR. Shifting our focus from NASH to MASH. Gastroenterol Hepatol (N. Y). 2023;19:511 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10524405\/pdf\/GH_19_9_511.pdf","journal-title":"Gastroenterol Hepatol (N. Y)"},{"key":"1396_CR5","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79 j","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79 j:1542\u201356. https:\/\/www.journal-of-hepatology.eu\/action\/showPdf?pii=S0168-8278%2823%2900418-X December","journal-title":"J Hepatol"},{"key":"1396_CR6","unstructured":"American Association for the Study of Liver Diseases. New MASLD Nomenclature. 2023. https:\/\/www.aasld.org\/new-masld-nomenclature"},{"key":"1396_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341\u201350. https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMra0912063?articleTools=true","journal-title":"N Engl J Med"},{"key":"1396_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-020-00097-1","volume":"6","author":"S Tomah","year":"2020","unstructured":"Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do diabetologists stand? Clin Diabetes Endocrinol. 2020;6:9 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7275502\/pdf\/40842_2020_Article_97.pdf","journal-title":"Clin Diabetes Endocrinol"},{"key":"1396_CR9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063\u201372. https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMra1503519?articleTools=true","journal-title":"N Engl J Med"},{"key":"1396_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357. https:\/\/journals.lww.com\/hep\/fulltext\/2018\/01000\/the_diagnosis_and_management_of_nonalcoholic_fatty.31.aspx","journal-title":"Hepatology"},{"key":"1396_CR11","unstructured":"REZDIFFRA (resmetirom) tablets, for oral use Initial U.S. Approval: 14March 2024 (Drug Label) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217785s000lbl.pdf"},{"key":"1396_CR12","first-page":"605","volume":"8","author":"NH Afdhal","year":"2012","unstructured":"Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N. Y). 2012;8:605\u20137. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3594956\/pdf\/GH-08-605.pdf","journal-title":"Gastroenterol Hepatol (N. Y)"},{"key":"1396_CR13","doi-asserted-by":"publisher","first-page":"101167","DOI":"10.1016\/j.molmet.2021.101167","volume":"50","author":"V Ajmera","year":"2021","unstructured":"Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab. 2021;50:101167 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8324681\/pdf\/main.pdf","journal-title":"Mol Metab"},{"key":"1396_CR14","doi-asserted-by":"publisher","first-page":"1254014","DOI":"10.1155\/2022\/1254014","volume":"2022","author":"Y Zeng","year":"2022","unstructured":"Zeng Y, He H, An Z. Advance of serum biomarkers and combined diagnostic panels in nonalcoholic fatty liver disease. Dis Markers. 2022;2022:1254014 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9259243\/pdf\/DM2022-1254014.pdf","journal-title":"Dis Markers"},{"key":"1396_CR15","unstructured":"A Brief History of the Center for Drug Evaluation and Research. 01\/31\/2018. https:\/\/www.fda.gov\/about-fda\/fda-history-exhibits\/brief-history-center-drug-evaluation-and-research"},{"key":"1396_CR16","unstructured":"FDA Center for Drug Evaluation Director-designate Carl Peck. PINK SHEET 05 Oct 1987. https:\/\/scrip.citeline.com\/PS012562\/FDA-Center-for-Drug-Evaluation-Director-designate-Carl-Peck"},{"key":"1396_CR17","unstructured":"Drug and Biological Product Consolidation. Federal Register \/ Vol. 68, No. 123 \/ Thursday, June 26, 2003 \/ Notices. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2003-06-26\/pdf\/03-16242.pdf"},{"key":"1396_CR18","unstructured":"FDA Office of New Drugs (OND) Annual Report (2022). https:\/\/www.fda.gov\/media\/172747\/download?attachment"},{"key":"1396_CR19","unstructured":"CFR - Code of Federal Regulations Title 21. INVESTIGATIONAL NEW DRUG APPLICATION. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRsearch.cfm?CFRPart=312"},{"key":"1396_CR20","unstructured":"Personal Communication, Brian E Harvey MD PhD. March 17, 2024"},{"key":"1396_CR21","unstructured":"Modernizing FDA\u2019s New Drugs Regulatory Program. 12\/05\/2023 https:\/\/www.fda.gov\/drugs\/regulatory-science-research-and-education\/modernizing-fdas-new-drugs-regulatory-program"},{"key":"1396_CR22","unstructured":"Division of Hepatology and Nutrition (DHN). 08\/11\/2020. https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-immunology-and-inflammation-division-hepatology-and-nutrition-dhn"},{"key":"1396_CR23","unstructured":"Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed modernization of FDA\u2019s drug review office. June 04, 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-proposed-modernization-fdas-drug-review-office"},{"key":"1396_CR24","unstructured":"FDA Guidance for Industry Expedited Programs for Serious Conditions \u2013 Drugs and Biologics. May 2014. https:\/\/www.fda.gov\/media\/86377\/download"},{"key":"1396_CR25","unstructured":"Breakthrough Therapy Designation. 01\/04\/2018. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/breakthrough-therapy"},{"key":"1396_CR26","unstructured":"Fast Track. 01\/04\/2018. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/fast-track"},{"key":"1396_CR27","unstructured":"Priority Review. 01\/04\/2018. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/priority-review"},{"key":"1396_CR28","unstructured":"Accelerated Approval. 02\/24\/2023. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval"},{"key":"1396_CR29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s43441-022-00430-z","volume":"56","author":"G Beakes-Read","year":"2022","unstructured":"Beakes-Read G, Neisser M, Frey P, Guarducci M. Analysis of FDA\u2019s accelerated approval program performance december 1992\u2013december 2021. Ther Innov Regul Sci. 2022;56:698\u2013703. https:\/\/doi.org\/10.1007\/s43441-022-00430-z","journal-title":"Ther Innov Regul Sci"},{"key":"1396_CR30","unstructured":"Accelerated Approval Update under Food and Drug Omnibus Report Act of 2022 (FDORA). https:\/\/www.congress.gov\/117\/bills\/hr2617\/BILLS-117hr2617enr.pdf"},{"key":"1396_CR31","unstructured":"Final Decision on the Proposal to Withdraw Approval of Pepaxto (melphalan flufenamide) for Injection Docket No. FDA-2023-N-3167 February 23, 2024. https:\/\/www.fda.gov\/media\/176510\/download?attachment"},{"key":"1396_CR32","unstructured":"FDA issues final decision to withdraw approval of Pepaxto (melphalan flufenamide). 02\/23\/2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-issues-final-decision-withdraw-approval-pepaxto-melphalan-flufenamide"},{"key":"1396_CR33","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","volume":"54","author":"Endpoints and clinical trial design for nonalcoholic steatohepatitis.","year":"2011","unstructured":"Endpoints and clinical trial design for nonalcoholic steatohepatitis. (AASLD 2009 Workshop Endpoints in Nonalcoholic Steatohepatitis). Hepatology. 2011;54:344\u201353. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4014460\/pdf\/nihms289374.pdf","journal-title":"Hepatology"},{"key":"1396_CR34","unstructured":"FDA Guidance Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment (Draft). December 2018. https:\/\/www.fda.gov\/media\/119044\/download"},{"key":"1396_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/hep4.1079","volume":"1","author":"C Filozof","year":"2017","unstructured":"Filozof C, Chow SC, Dimick\u2010Santos L, Chen YF, Williams RN, Goldstein BJ, et al. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. Hepatol Commun. 2017;1:577\u201385. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5721443\/pdf\/HEP4-1-577.pdf","journal-title":"Hepatol Commun"},{"key":"1396_CR36","unstructured":"Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality. 05\/21\/2020. https:\/\/www.fda.gov\/drugs\/regulatory-science-research-and-education\/reorganization-office-new-drugs-corresponding-changes-office-translational-sciences-and-office"},{"key":"1396_CR37","unstructured":"Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry (Draft). June 2019. https:\/\/www.fda.gov\/media\/127738\/download"},{"key":"1396_CR38","unstructured":"Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis (NASH) October 20, 2016 https:\/\/ir.madrigalpharma.com\/node\/8641\/pdf"},{"key":"1396_CR39","unstructured":"NCT02912260. Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02912260?term=NCT02912260&draw=2&rank=1"},{"key":"1396_CR40","unstructured":"Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH. August 21, 2017. https:\/\/ir.madrigalpharma.com\/node\/12566\/pdf"},{"key":"1396_CR41","unstructured":"Madrigal\u2019s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial. May 31, 2018. https:\/\/ir.madrigalpharma.com\/node\/12791\/pdf"},{"key":"1396_CR42","unstructured":"Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH). November 11, 2019. https:\/\/ir.madrigalpharma.com\/node\/13201\/pdf"},{"key":"1396_CR43","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012\u201324. https:\/\/www.natap.org\/2022\/HCV\/PIIS01406736193251762.pdf Nov 30","journal-title":"Lancet"},{"key":"1396_CR44","unstructured":"Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis March 28, 2019. https:\/\/ir.madrigalpharma.com\/node\/13036\/pdf"},{"key":"1396_CR45","unstructured":"NCT03900429. A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03900429?term=Resmetirom&draw=2&rank=4"},{"key":"1396_CR46","unstructured":"Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH. December 18, 2019. https:\/\/ir.madrigalpharma.com\/node\/13251\/pdf"},{"key":"1396_CR47","unstructured":"NCT04197479. A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients (MAESTRO-NAFLD1). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04197479?term=Resmetirom&draw=2&rank=1"},{"key":"1396_CR48","unstructured":"Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom. June 30, 2021. https:\/\/ir.madrigalpharma.com\/node\/13726\/pdf"},{"key":"1396_CR49","unstructured":"Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study. July 13, 2021. https:\/\/ir.madrigalpharma.com\/node\/13736\/pdf"},{"key":"1396_CR50","unstructured":"NCT04951219. A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04951219?term=Resmetirom&draw=2&rank=2"},{"key":"1396_CR51","unstructured":"Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health. January 31, 2022. https:\/\/ir.madrigalpharma.com\/node\/14121\/pdf"},{"key":"1396_CR52","unstructured":"Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis. August 31, 2022. https:\/\/ir.madrigalpharma.com\/node\/14471\/pdf"},{"key":"1396_CR53","unstructured":"NCT05500222. A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05500222?term=Resmetirom&draw=2&rank=3"},{"key":"1396_CR54","unstructured":"Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis. December 19, 2022. https:\/\/ir.madrigalpharma.com\/node\/14516\/pdf"},{"key":"1396_CR55","unstructured":"Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial. April 18, 2023. https:\/\/ir.madrigalpharma.com\/node\/14701\/pdf"},{"key":"1396_CR56","unstructured":"Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis. September 13, 2023. https:\/\/ir.madrigalpharma.com\/node\/14951\/pdf"},{"key":"1396_CR57","unstructured":"Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine. February 8, 2024. https:\/\/ir.madrigalpharma.com\/node\/15291\/pdf"},{"key":"1396_CR58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"1396_CR59","unstructured":"Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra\u2122 (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis. March 14, 2024. https:\/\/ir.madrigalpharma.com\/node\/15401\/pdf"},{"key":"1396_CR60","unstructured":"FDA LETTER. NDA 217785 ACCELERATED APPROVAL. March 14, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2024\/217785Orig1s000ltr.pdf"},{"key":"1396_CR61","unstructured":"Division of Cardiology and Nephrology https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-cardiology-hematology-endocrinology-and-nephrology-ochen-division-cardiology-and-nephrology"},{"key":"1396_CR62","unstructured":"Division of Diabetes, Lipid Disorders, and Obesity https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-cardiology-hematology-endocrinology-and-nephrology-division-diabetes-lipid-disorders-and"},{"key":"1396_CR63","unstructured":"Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN). https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-cardiology-hematology-endocrinology-and-nephrology-ochen"},{"key":"1396_CR64","unstructured":"JARDIANCE\u00ae (empagliflozin tablets) Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204629s040lbl.pdf"},{"key":"1396_CR65","unstructured":"FDA Jardiance Supplement Approval Letter (August 18, 2021) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/204629Orig1s026ltr.pdf"},{"key":"1396_CR66","unstructured":"FDA Jardiance Supplement Approval Letter (September 21, 2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/204629Orig1s040ltr.pdf"},{"key":"1396_CR67","unstructured":"Office of Immunology and Inflammation (OII). https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-immunology-and-inflammation-oii"},{"key":"1396_CR68","unstructured":"Office of New Drugs (OND) \u201cSuper Office\u201d. https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-new-drugs"},{"key":"1396_CR69","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/hep.31687","volume":"73","author":"FA Anania","year":"2021","unstructured":"Anania FA, Dimick-Santos L, Mehta R, Toerner J, Beitz J. Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the food and drug administration. Hepatology. 2021;73:2023\u20137. https:\/\/doi.org\/10.1002\/hep.31687","journal-title":"Hepatology"},{"key":"1396_CR70","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41401-021-00832-z","volume":"43","author":"BE Harvey","year":"2022","unstructured":"Harvey BE. NASH: regulatory considerations for clinical drug development and U.S. FDA approval. Acta Pharmacol Sin. 2022;43:1210\u20134. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9061714\/pdf\/41401_2021_Article_832.pdf","journal-title":"Acta Pharmacol Sin."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01396-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01396-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01396-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:17:24Z","timestamp":1740129444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01396-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1038\/s41401-024-01396-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"9 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}